Neil Varshneya

Dr. Neil Varshneya

Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
Neil VarshneyaNeil Varshneya
Neil Varshneya
ATAshish P. Thakrar
Ashish P. Thakrar
JHJ. Gregory Hobelmann
J. Gregory Hobelmann
KDKelly E. PhD Dunn
Kelly E. PhD Dunn
AHAndrew S. PhD Huhn
Andrew S. PhD Huhn
Objectives: Buprenorphine can precipitate withdrawal in opioid-dependent persons with recent fentanyl use. However, the prevalence of this phenomenon is not clinically established. We sought to evaluate the incidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. Methods: We collected self-report data on opioid withdrawal symptoms after buprenorphine use, and, as a comparator, after methadone use, in 1679 individuals seeking treatment for opioid use disorder across 49 addiction treatment centers in the United States. Results: The odds of developing severe withdrawal symptoms significantly increased when taking buprenorphine within 24 hours after fentanyl use (OR = 5.202, 95% CI = 1.979–13.675, P = 0.001), and within 24 to 48hours after fentanyl use (OR = 3.352, 95% CI =1.237–9.089, P = 0.017). As expected, patients did not report significantly higher rates of withdrawal when taking methadone after fentanyl use. Of those who waited less than 24hours after fentanyl before using buprenorphine or methadone, 22.19% (n = 152 of 685) and 11.56% (n = 23 of 199), respectively, reported severe opioid withdrawal. Conclusions: This study supports previous anecdotal reports of buprenorphine-precipitated withdrawal from fentanyl. The odds of withdrawal symptoms significantly increased when taking buprenorphine after recent (within 48 hours) fentanyl use, however, this relationship was not observed in persons taking methadone, suggesting that this effect is specific to buprenorphine. Further research is urgently needed to describe the pharmacokinetics of non-medical fentanyl use to improve buprenorphine inductions strategies.

19 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
Neil VarshneyaNeil Varshneya
Neil Varshneya
SHSherif H. Hassanien
Sherif H. Hassanien
MHMelissa C. Holt
Melissa C. Holt
DSDavid L. Stevens
David L. Stevens
NLNathan K. Layle
Nathan K. Layle
PBPatrick M. Beardsley
Patrick M. Beardsley

20 March 2019 in Neuropharmacology
Verified
Journal Article
Closed access
Neil VarshneyaNeil Varshneya
Neil Varshneya
DWD. Matthew Walentiny
D. Matthew Walentiny
LMLea T. Moisa
Lea T. Moisa
TWTeneille D. Walker
Teneille D. Walker
LALuli R. Akinfiresoye
Luli R. Akinfiresoye
PBPatrick M. Beardsley
Patrick M. Beardsley

21 July 2021 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
Neil VarshneyaNeil Varshneya
Neil Varshneya
DWD. Matthew Walentiny
D. Matthew Walentiny
LMLea T. Moisa
Lea T. Moisa
TWTeneille D. Walker
Teneille D. Walker
LALuli R. Akinfiresoye
Luli R. Akinfiresoye
PBPatrick M. Beardsley
Patrick M. Beardsley

24 May 2023 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
Neil VarshneyaNeil Varshneya
Neil Varshneya
SHSherif H. Hassanien
Sherif H. Hassanien
MHMelissa C. Holt
Melissa C. Holt
DSDavid L. Stevens
David L. Stevens
NLNathan K. Layle
Nathan K. Layle
PBPatrick M. Beardsley
Patrick M. Beardsley

1 May 2020 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
SNSara Nass
Sara Nass
YHYun K. Hahn
Yun K. Hahn
VMVirginia D. McLane
Virginia D. McLane
Neil VarshneyaNeil Varshneya
Neil Varshneya
MDM. Imad Damaj
M. Imad Damaj
KHKurt F Hauser
Kurt F Hauser
HIV-1 selectively disrupts neuronal integrity within specific brain regions, reflecting differences in viral tropism and/or the regional differences in the vulnerability of distinct neuronal subpopulations within the CNS. Deficits in prefrontal cortex (PFC)-mediated executive function and the resultant loss of behavioral control are a particularly debilitating consequence of neuroHIV. To explore how HIV-1 disrupts executive function, we investigated the effects of 48 h, 2 and/or 8 weeks of HIV-1 Tat exposure on behavioral control, synaptic connectivity, and neuroimmune function in the anterior cingulate cortex (ACC) and associated cortico-basal ganglia (BG)-thalamocortical circuitry in adult, Tat transgenic male mice. HIV-1 Tat exposure increased novelty-exploration in response to novel food, flavor, and environmental stimuli, suggesting that Tat triggers increased novelty-exploration in situations of competing motivation (e.g., drive to feed or explore vs. fear of novel, brightly lit open areas). Furthermore, Tat induced adaptability in response to an environmental stressor and pre-attentive filtering deficits. The behavioral insufficiencies coincided with decreases in the inhibitory pre- and post-synaptic proteins, synaptotagmin 2 and gephyrin, respectively, in the ACC, and alterations in specific pro- and anti-inflammatory cytokines out of 23 assayed. The interaction of Tat exposure and the resultant time-dependent, selective alterations in CCL4, CXCL1, IL-12p40, and IL-17A levels in the PFC predicted significant decreases in adaptability. Tat decreased dendritic spine density and cortical VGLUT1 inputs, while increasing IL-1β, IL-6, CCL5, and CCL11 in the striatum. Alternatively, IL-1α, CCL5, and IL-13 were decreased in the mediodorsal thalamus despite the absence of synaptic changes. Thus, HIV-1 Tat appears to uniquely and systematically disrupt immune regulation and the inhibitory and excitatory synaptic balance throughout the ACC-BG-thalamocortical circuitry resulting in a loss of behavioral control.